Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2003 1
2004 1
2005 2
2006 1
2007 4
2008 3
2009 2
2010 7
2011 6
2012 4
2013 12
2014 11
2015 13
2016 9
2017 7
2018 8
2019 4
2020 1
2021 6
2022 8
2023 10
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

109 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis.
Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa Y, Leucht S, Ruhe HG, Turner EH, Higgins JPT, Egger M, Takeshima N, Hayasaka Y, Imai H, Shinohara K, Tajika A, Ioannidis JPA, Geddes JR. Cipriani A, et al. Lancet. 2018 Apr 7;391(10128):1357-1366. doi: 10.1016/S0140-6736(17)32802-7. Epub 2018 Feb 21. Lancet. 2018. PMID: 29477251 Free PMC article. Review.
In terms of efficacy, all antidepressants were more effective than placebo, with ORs ranging between 2.13 (95% credible interval [CrI] 1.89-2.41) for amitriptyline and 1.37 (1.16-1.63) for reboxetine. For acceptability, only agomelatine (OR 0.84, 95% CrI 0.72-0.97) and flu …
In terms of efficacy, all antidepressants were more effective than placebo, with ORs ranging between 2.13 (95% credible interval [CrI] 1.89- …
Antidepressant efficacy of Agomelatine: Meta-analysis of placebo controlled and active comparator studies.
Maddukuri RK, Hema C, Sri Tejaswi K, Venkata Mounika M, Vegesana BP. Maddukuri RK, et al. Asian J Psychiatr. 2021 Nov;65:102866. doi: 10.1016/j.ajp.2021.102866. Epub 2021 Sep 20. Asian J Psychiatr. 2021. PMID: 34592623 Review.
Agomelatine is a novel antidepressant that was developed to counter the adverse effects associated with the standard SSRIs and SNRIs that limited their usage. ...In comparison (RR 0.99, 0.92-1.07) Agomelatine is an effective antidepressant having similar efficacy wi
Agomelatine is a novel antidepressant that was developed to counter the adverse effects associated with the standard SSRIs and SNRIs
Agomelatine augmentation of sertraline in the treatment of moderate to severe obsessive-compulsive disorder: a randomized double-blinded placebo-controlled clinical trial.
Shokrani M, Askari S, Eissazade N, Shariat SV, Shariati B, Yarahmadi M, Shalbafan M. Shokrani M, et al. BMC Psychiatry. 2023 Sep 21;23(1):686. doi: 10.1186/s12888-023-05189-7. BMC Psychiatry. 2023. PMID: 37735631 Free PMC article. Clinical Trial.
They were assigned with sertraline (100 mg/day for the first 4 weeks and 200 mg/day for the next 8 weeks) and either agomelatine (25 mg/day) or placebo. The primary outcome was OCD symptoms measured by the Y-BOCS. RESULTS: Fifty patients (24 in agomelatine group and …
They were assigned with sertraline (100 mg/day for the first 4 weeks and 200 mg/day for the next 8 weeks) and either agomelatine (25 …
Agomelatine efficacy and acceptability revisited: systematic review and meta-analysis of published and unpublished randomised trials.
Koesters M, Guaiana G, Cipriani A, Becker T, Barbui C. Koesters M, et al. Br J Psychiatry. 2013 Sep;203(3):179-87. doi: 10.1192/bjp.bp.112.120196. Br J Psychiatry. 2013. PMID: 23999482 Review.
BACKGROUND: Agomelatine is a novel antidepressant drug with narrative, non-systematic reviews making claims of efficacy. ...Data extracted from three relapse prevention studies failed to show significant effects of agomelatine over placebo (relative risk 0.78, 99% C …
BACKGROUND: Agomelatine is a novel antidepressant drug with narrative, non-systematic reviews making claims of efficacy. ...Data extr …
Agomelatine versus other antidepressive agents for major depression.
Guaiana G, Gupta S, Chiodo D, Davies SJ, Haederle K, Koesters M. Guaiana G, et al. Cochrane Database Syst Rev. 2013 Dec 17;(12):CD008851. doi: 10.1002/14651858.CD008851.pub2. Cochrane Database Syst Rev. 2013. PMID: 24343836 Review.
OBJECTIVES: The objective of this review was 1) to determine the efficacy of agomelatine in alleviating acute symptoms of major depressive disorder in comparison with other antidepressants, 2) to review the acceptability of agomelatine in comparison with other antid …
OBJECTIVES: The objective of this review was 1) to determine the efficacy of agomelatine in alleviating acute symptoms of major depre …
Efficacy of agomelatine in major depressive disorder: meta-analysis and appraisal.
Singh SP, Singh V, Kar N. Singh SP, et al. Int J Neuropsychopharmacol. 2012 Apr;15(3):417-28. doi: 10.1017/S1461145711001301. Epub 2011 Aug 23. Int J Neuropsychopharmacol. 2012. PMID: 21859514 Free article. Review.
Summary effect sizes of various groups and subgroups were computed from SMDs between agomelatine and control (placebo or antidepressants) arms. There were nine trials involving 3943 severe cases of depression on agomelatine (n=2390) and either placebo (n=689) or ant …
Summary effect sizes of various groups and subgroups were computed from SMDs between agomelatine and control (placebo or antidepressa …
Antidepressant efficacy of agomelatine: meta-analysis of published and unpublished studies.
Taylor D, Sparshatt A, Varma S, Olofinjana O. Taylor D, et al. BMJ. 2014 Mar 19;348:g1888. doi: 10.1136/bmj.g1888. BMJ. 2014. PMID: 24647162 Free PMC article. Review.
DATA SOURCES: Literature search (Pubmed, Embase, Medline), Cochrane Central Register of Controlled Trials, European Medicines Agency (EMA) regulatory file for agomelatine, manufacturers of agomelatine (Servier). ELIGIBILITY CRITERIA: Double blind randomised placebo …
DATA SOURCES: Literature search (Pubmed, Embase, Medline), Cochrane Central Register of Controlled Trials, European Medicines Agency (EMA) r …
Antidepressants for the treatment of adults with major depressive disorder in the maintenance phase: a systematic review and network meta-analysis.
Kishi T, Ikuta T, Sakuma K, Okuya M, Hatano M, Matsuda Y, Iwata N. Kishi T, et al. Mol Psychiatry. 2023 Jan;28(1):402-409. doi: 10.1038/s41380-022-01824-z. Epub 2022 Oct 17. Mol Psychiatry. 2023. PMID: 36253442 Free PMC article.
The meta-analysis comprised 34 studies (n = 9384, mean age = 43.80 years, and %females = 68.10%) on 20 antidepressants (agomelatine, amitriptyline, bupropion, citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, fluvoxamine, levomilnacipran, milnacipran, mirta …
The meta-analysis comprised 34 studies (n = 9384, mean age = 43.80 years, and %females = 68.10%) on 20 antidepressants (agomelatine, …
Efficacy and safety of agomelatine in the treatment of patients with depressive disorder: A meta-analysis.
Guo YH, Zhou L, Cui ZA, Wang J, Zhang L, Xu T, Xie YD, Chen H. Guo YH, et al. Medicine (Baltimore). 2023 Nov 10;102(45):e35871. doi: 10.1097/MD.0000000000035871. Medicine (Baltimore). 2023. PMID: 37960759 Free PMC article.
OBJECTIVE: To systematically assess the efficacy and safety of agomelatine in the treatment of patients with depressive disorder. METHODS: Randomized controlled trials (RCTs) related to agomelatine in the treatment of patients with depressive disorder published in P …
OBJECTIVE: To systematically assess the efficacy and safety of agomelatine in the treatment of patients with depressive disorder. MET …
Agomelatine might be more appropriate for elderly, depressed, type 2 diabetes mellitus patients than paroxetine/fluoxetine.
Liang Z, Jia Y, Zhao L, Zhu R, He X, Tong B, Yang F, Hao L, Cui P, Yuan J. Liang Z, et al. Aging (Albany NY). 2021 Oct 5;13(19):22934-22946. doi: 10.18632/aging.203586. Epub 2021 Oct 5. Aging (Albany NY). 2021. PMID: 34610580 Free PMC article. Clinical Trial.
Agomelatine was a novel and melatonergic antidepressant. The present study was conducted to find out whether age was an important factor for agomelatine in treating depressed type 2 diabetes mellitus (T2DM) patients. ...These results suggested that age was an import
Agomelatine was a novel and melatonergic antidepressant. The present study was conducted to find out whether age was an important fac
109 results